CD274 and plasma cell myeloma: In a mouse model of multiple myeloma, BMSCs have been reported to suppress T cell-mediated immune responses via the PD-1/PD-L1 signaling pathway, including by inhibiting the proliferation of CD4+ T cells, reducing the Th1/Th17 ratio, and increasing the levels of Th2 and Treg cells.